Crescent Biopharma completed dose escalation in its global Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody, with over 125 patients dosed and plans to report initial monotherapy data for non-small cell lung cancer in Q1 2027. The company is also progressing multiple Phase 2 studies in China with partner Kelun-Biotech and has started dosing in a global Phase 1/2 trial of CR-002, a PD-L1-targeted antibody-drug conjugate. Crescent reported a net loss of $37.7 million for Q3 2026 but holds $289.4 million in cash, expected to fund operations into late 2028. Key clinical data readouts are anticipated throughout 2027, positioning Crescent to potentially initiate Phase 3 trials for CR-001 in early 2028.
Crescent Biopharma's recent financial results and clinical progress provide context for health sector performance on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: Of 150 priced health-sector US stocks, 23 rose and 124 fell today. Novavax Inc (NVAX) dropped 12.32% to USD 8.75 with a typical hold time of 60 days and 99% buy orders, contrasting with Citius Pharmaceuticals Inc (CTXR) which gained 11.19% to USD 0.53 despite 84% sell orders and a shorter hold time of 19 days. Sana Biotechnology Inc (SANA) fell 11.79% to USD 2.02 with a 40% sell order ratio and a 26-day hold time.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
